Travere Therapeutics (NASDAQ:TVTX) CFO Christopher Cline Sells 7,242 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Christopher Cline sold 7,242 shares of the company’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $32.12, for a total value of $232,613.04. Following the transaction, the chief financial officer directly owned 112,971 shares in the company, valued at $3,628,628.52. This represents a 6.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Travere Therapeutics Price Performance

Shares of NASDAQ TVTX opened at $32.84 on Wednesday. The company has a debt-to-equity ratio of 4.23, a quick ratio of 2.71 and a current ratio of 2.75. Travere Therapeutics, Inc. has a one year low of $12.91 and a one year high of $42.13. The firm has a market capitalization of $2.94 billion, a P/E ratio of -30.98, a PEG ratio of 1.01 and a beta of 0.83. The company’s fifty day moving average is $34.11 and its two-hundred day moving average is $27.76.

Key Stories Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Negative Sentiment: Multiple senior insiders sold large blocks of shares on Feb 3, including CEO Eric M. Dube (100,087 shares, ~18.8% reduction in his position) and several executives (CFO, CAO and other officers) reducing holdings by ~5–10% each — a broad, same-day executive sell-off that can signal rotation or prompt investor concern about near-term insider confidence. CEO Form 4
• Negative Sentiment: A recent article questions Travere’s disclosure and risk narrative, flagging potential credibility concerns that could amplify selling or increase short-term volatility if investors seek more clarity from management. Is Travere Therapeutics (TVTX) Facing a Credibility Test in Its Disclosure and Risk Narrative?

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Piper Sandler raised their price objective on Travere Therapeutics from $26.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Guggenheim reaffirmed a “buy” rating and set a $49.00 price target on shares of Travere Therapeutics in a research note on Wednesday, January 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. HC Wainwright restated a “buy” rating and set a $47.00 target price on shares of Travere Therapeutics in a research report on Friday, November 28th. Finally, Zacks Research cut shares of Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $38.86.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Arizona State Retirement System grew its holdings in Travere Therapeutics by 1.5% in the third quarter. Arizona State Retirement System now owns 24,964 shares of the company’s stock valued at $597,000 after purchasing an additional 375 shares during the period. Comerica Bank raised its holdings in shares of Travere Therapeutics by 77.5% in the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock worth $43,000 after purchasing an additional 492 shares during the period. Prudential Financial Inc. grew its holdings in shares of Travere Therapeutics by 0.3% during the 2nd quarter. Prudential Financial Inc. now owns 244,256 shares of the company’s stock worth $3,615,000 after purchasing an additional 615 shares during the period. Teacher Retirement System of Texas raised its holdings in Travere Therapeutics by 3.5% in the second quarter. Teacher Retirement System of Texas now owns 22,688 shares of the company’s stock valued at $336,000 after buying an additional 773 shares during the period. Finally, Diversified Trust Co increased its position in shares of Travere Therapeutics by 3.5% in the third quarter. Diversified Trust Co now owns 23,695 shares of the company’s stock worth $566,000 after acquiring an additional 796 shares in the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.